CONSIDERATIONS TO KNOW ABOUT ABBV-744 BRD4 INHIBITOR CANCER THERAPY EFFICACY

In Section A, participants will acquire distinctive doses and schedules of oral ABBV-744 tablet to recognize Protected dosing program. Supplemental members are going to be enrolled within the determined monotherapy dosign regimen. In Section B, individuals will acquire oral ruxolitinib and ABBV-744 is going to be provided as "insert-on" therapy. In